Phase 3 N=43 A Study of Galunisertib in Participants With Myelodysplastic Syndromes
Myelodysplastic Syndromes
Primary: Percentage of Participants With Hematological Improvement (HI) — 31.7; 0.0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=182 Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)
Anesthesia, General
Primary: Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Rocuronium — 3.28; 55.50…
Phase 3 N=20 Phenylbutyrate Therapy for Maple Syrup Urine Disease
Maple Syrup Urine Disease
Primary: 0-24 Hour AUC Leucine (Samples Collected at 0, 2, 4, 8, 12, 16, 20, and 24 Hours) — 6217; 4616 micromoles*hour/L
Phase 3 N=498 Simplifying the Rabies Pre-exposure Vaccination
Rabies
Primary: Number of Participants With a Boostability of the Rabies Antibodies After Booster Vaccination — 185; 183 Participants
Phase 3 N=266 A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
Psoriasis
Primary: Percentage of Participants With Physician's Global Assessment (PGA) Score of "Clear" or "Almost Clear" at Week 16 — 75.56; 52.27; 19.32 percentage of participants…
Phase 3 N=249 Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Adult Kidney Wilms Tumor · Beckwith-Wiedemann Syndrome · Childhood Kidney Wilms Tumor
Primary: Event-Free Survival (EFS) — 0.82 Probability
Phase 3 N=45 Oral vs. Injectable Naltrexone for Hospitalized Veterans With Alcohol Dependence
Alcohol Dependence
Primary: Retention Rate: Percentage of Participants Attended an Initial Behavioral Treatment Visit Within 2 Weeks of Hospital Discharge. — 23; 22 Participants
Phase 3 N=25 Trial of Leptin Replacement Therapy in Patients With Lipodystrophy
Hypoleptinemia · Generalized Lipodystrophy · Partial Lipodystrophy
Primary: Fasting Serum Triglycerides — 203; 304 mg/dL — p=0.2572
Phase 3 N=806 Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
Prostatic Neoplasms
Primary: Symptomatic Skeletal Event Free Survival (SSE-FS) — 22.3; 26.0 Months — p=0.2636
Phase 3 N=200 Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2)
Malaria · Human Immunodeficiency Virus
Primary: Number of Participants With Placental Malaria — 3; 6 Participants — p=0.50
Phase 3 N=101 A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment
Hepatitis C Virus (HCV)
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post Dosing (SVR12) — 97.0 percentage of participants
Phase 3 N=707 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 10.2; 8.0 months — p=0.0049
Phase 3 N=405 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Liver Cancer · Anxiety Disorder · Depression
Primary: Change in Quality of Life (QOL) From Baseline to Week 12 Per the Functional Assessment of Cancer Therapy-General (FACT-G) — 3.35; 0.12 units on a scale — p=0.104
Phase 3 N=404 A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants
Parkinson's Disease
Primary: Change From Baseline in Mean Daily OFF-time During Treatment Period — -0.51; -1.11; -1.35 hours per day — p=0.0006
Phase 3 N=198 A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants
Parkinson's Disease
Primary: Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) — 51; 91 Participants